This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Regeneron Pharmaceuticals, Inc.
Drug Names(s): Pegylated AXOKINE
Description: Regeneron developed this chemically modified version of AXOKINE as a potentially more potent and longer-lasting molecule. AXOKINE is currently being evaluated in a large Phase III program for overweight and obese patients.
Partners: Nektar Therapeutics
Additional information available to subscribers only: